Strengths
Lilly 30x30 infrastructure and impact
Insulin price reductions and manufacturing partnerships.
Growing Health Systems Strengthening efforts through partnerships
Enhanced public transparency and reporting on 30x30 impact
Strong NCD-focused portfolio addressing critical global health needs
Expanded affordability measures, including voluntary licensing
Weaknesses
Lack of enterprise-wide coordinated strategy and framework for global health equity. Large volume of initiatives and firewalled structure may lead to silo efforts and reduced impact
30x30 lack of internal prioritization could hinder implementation and impact
Existing business models in LMICs limiting tailored implementation on the ground
Limited geographic reach in LMICs
Opportunities:
Growing global NCD burden, especially in LMICs (e.g. obesity, oncology, autoimmune and inflammatory, cardiometabolic)
Alternative business models to scale access
Strategic partnerships with organizations that have existing presence and infrastructure
Leveraging insulin affordability model to broaden access strategy
Digital health and technology optimization for decentralized care in low-resource settings
Scaling up manufacturing partnerships globally, inclusive of VLAs
Collaborative/innovative R&D models in LMICs
Threats:
Chronic underfunding of health systems in LMICs, prioritizing communicable diseases over NCDs
Heavy financial burden OOP for patients
Supply chain resilience issues
Geopolitical risks
Market dynamics limiting access to affordable biosimilars
Climate change and political instability impacting healthcare infrastructure